Goodwin Procter advised AlgoTx on the deal. AlgoTx announced its €20 million Series B. AlgoTx develops novel solutions for complex pain. Their lead program, ATX01, targets highly...
Goodwin Procter advised AlgoTx on the deal. AlgoTx announced its €20 million Series B. AlgoTx develops novel solutions for complex pain. Their lead program, ATX01, targets highly...
You must be a Standard 1 Year member to access this content.